MIRM on Nasdaq
Mirum Pharmaceuticals
Biopharmaceutical company.1
Price unavailable
Last updated Oct 18, 2026.
Overview
2018Founded1
Compare with BridgeBio, Hutchison China Meditech or Travere Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-4.2%Operating margin4
-4.5%Net margin4
54.7%Revenue growth, 20254
-7.4%Return on equity4
$54.9MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Livmarli brought in 69% of the revenue Mirum Pharmaceuticals broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Livmarli | $141.8M | $213.3M | $360.0M |
| Bile Acid Medicines | $37.1M | $123.1M | $161.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin49¢$257.0M
- Other costs50¢$262.3M
- Income tax0¢$1.9M
Out of $521.3M in revenue.4 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending2¢$954.0K
- Kept or used elsewhere98¢$54.9M
Out of $55.8M of cash from operations.4
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $521.3M | $336.9M | $186.4M |
| Cost of sales | $100.2M | $81.6M | $47.0M |
| Research and development | $186.2M | $140.6M | $102.6M |
| Selling, general and administrative | $257.0M | $202.2M | $145.9M |
| Total operating expenses | $543.4M | $424.5M | $295.5M |
| Loss from operations | -$22.1M | -$87.6M | -$109.2M |
| Interest income | $12.7M | $13.8M | $13.7M |
| Interest expense | -$14.4M | -$14.3M | -$15.1M |
| Loss from termination of revenue interest purchase agreement | $0 | $0 | -$49.1M |
| Other income (expense), net | $2.4M | $1.2M | -$2.8M |
| Loss before provision for income taxes | -$21.4M | -$86.9M | -$162.4M |
| Provision for income taxes | $1.9M | $1.0M | $991.0K |
| Net loss | -$23.4M | -$87.9M | -$163.4M |
| Net loss per share, basic (in dollars per share) | -$0.47 | -$1.85 | -$4.00 |
| Net loss per share, diluted (in dollars per share) | -$0.47 | -$1.85 | -$4.00 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 50.2M shares | 47.5M shares | 40.9M shares |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 50.2M shares | 47.5M shares | 40.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $296.7M | $222.5M | ||
| Short-term investments | $86.6M | $57.8M | ||
| Accounts receivable | $123.3M | $78.3M | ||
| Inventory | $24.9M | $22.4M | ||
| Prepaid expenses and other current assets | $18.1M | $11.8M | ||
| Total current assets | $549.7M | $392.8M | ||
| Restricted cash | $1.5M | $425.0K | ||
| Long-term investments | $8.1M | $12.5M | ||
| Property and equipment, net | $1.9M | $1.1M | ||
| Operating lease right-of-use assets | $8.7M | $8.7M | ||
| Intangible assets, net | $260.9M | $249.8M | ||
| Other assets | $12.0M | $5.4M | ||
| Total assets | $842.8M | $670.8M | ||
| Accounts payable | $9.6M | $14.6M | ||
| Accrued expenses and other current liabilities | $196.2M | $111.9M | ||
| Total current liabilities | $205.8M | $126.6M | ||
| Operating lease liabilities, noncurrent | $7.5M | $8.0M | ||
| Convertible notes payable, net, noncurrent | $309.8M | $308.1M | ||
| Other liabilities | $5.0M | $2.5M | ||
| Total liabilities | $528.1M | $445.1M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 51,896,391 and 48,338,096 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $5.0K | $5.0K | ||
| Additional paid-in capital | $981.9M | $870.2M | ||
| Accumulated deficit | -$667.5M | -$644.2M | ||
| Accumulated other comprehensive income (loss) | $351.0K | -$373.0K | ||
| Total stockholders equity | $314.7M | $225.6M | $248.7M | $142.0M |
| Total liabilities and stockholders equity | $842.8M | $670.8M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, shares, issued (in shares) | 51.9M shares | 48.3M shares | ||
| Common stock, shares, outstanding (in shares) | 51.9M shares | 48.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $296.7M | $222.5M | ||
| Short-term investments | $86.6M | $57.8M | ||
| Accounts receivable | $123.3M | $78.3M | ||
| Inventory | $24.9M | $22.4M | ||
| Prepaid expenses and other current assets | $18.1M | $11.8M | ||
| Total current assets | $549.7M | $392.8M | ||
| Restricted cash | $1.5M | $425.0K | ||
| Long-term investments | $8.1M | $12.5M | ||
| Property and equipment, net | $1.9M | $1.1M | ||
| Operating lease right-of-use assets | $8.7M | $8.7M | ||
| Intangible assets, net | $260.9M | $249.8M | ||
| Other assets | $12.0M | $5.4M | ||
| Total assets | $842.8M | $670.8M | ||
| Accounts payable | $9.6M | $14.6M | ||
| Accrued expenses and other current liabilities | $196.2M | $111.9M | ||
| Total current liabilities | $205.8M | $126.6M | ||
| Operating lease liabilities, noncurrent | $7.5M | $8.0M | ||
| Convertible notes payable, net, noncurrent | $309.8M | $308.1M | ||
| Other liabilities | $5.0M | $2.5M | ||
| Total liabilities | $528.1M | $445.1M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 51,896,391 and 48,338,096 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $5.0K | $5.0K | ||
| Additional paid-in capital | $981.9M | $870.2M | ||
| Accumulated deficit | -$667.5M | -$644.2M | ||
| Accumulated other comprehensive income (loss) | $351.0K | -$373.0K | ||
| Total stockholders equity | $314.7M | $225.6M | $248.7M | $142.0M |
| Total liabilities and stockholders equity | $842.8M | $670.8M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, shares, issued (in shares) | 51.9M shares | 48.3M shares | ||
| Common stock, shares, outstanding (in shares) | 51.9M shares | 48.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$23.4M | -$87.9M | -$163.4M |
| Stock-based compensation | $71.4M | $48.4M | $35.0M |
| Depreciation and amortization | $24.2M | $23.6M | $10.8M |
| Inventory reserves and firm commitment losses | $2.9M | $2.6M | $9.3M |
| Amortization of debt discount and offering costs | $1.7M | $1.7M | $1.1M |
| Loss from termination of revenue interest purchase agreement | $0 | $0 | $49.1M |
| Non-cash interest expense related to the revenue interest liability | $0 | $0 | $5.1M |
| Unrealized foreign exchange (gain) loss | -$1.7M | -$1.2M | $1.8M |
| Non-cash lease expense | $1.7M | $1.4M | $620.0K |
| Other | -$1.4M | -$795.0K | -$1.1M |
| Accounts receivable | -$48.1M | -$11.4M | -$44.0M |
| Prepaid and other current assets | -$5.8M | -$849.0K | -$3.6M |
| Inventory | -$8.4M | -$3.2M | -$974.0K |
| Other assets | -$5.7M | -$1.5M | -$511.0K |
| Accounts payable, accrued expenses and other liabilities | $50.1M | $40.3M | $30.8M |
| Operating lease liabilities | -$1.9M | -$782.0K | -$940.0K |
| Net cash provided by (used in) operating activities | $55.8M | $10.3M | -$70.9M |
| Purchase of investments | -$97.4M | -$89.0M | -$27.3M |
| Proceeds from maturities of investments | $74.4M | $19.9M | $153.0M |
| Purchase of property and equipment | -$954.0K | -$993.0K | -$109.0K |
| Cash paid for acquisition | $0 | $0 | -$212.8M |
| Payments made for additions to intangible assets | $0 | -$20.0M | -$20.0M |
| Net cash used in investing activities | -$24.0M | -$90.1M | -$107.2M |
| Proceeds from issuance of common stock in private placement, net of issuance costs | $0 | $0 | $202.2M |
| Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs | $0 | $0 | $14.5M |
| Proceeds from issuance of convertible notes, net | $0 | $0 | $305.3M |
| Proceeds from issuance of common stock pursuant to equity plans | $40.1M | $17.7M | $10.5M |
| Payments of deferred offering costs | $0 | $0 | -$281.0K |
| Payments on revenue interest liability | $0 | $0 | -$195.6M |
| Net cash provided by financing activities | $40.1M | $17.7M | $336.6M |
| Effect of exchange rate on cash, cash equivalents and restricted cash | $3.2M | -$1.3M | -$133.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $75.2M | -$63.4M | $158.3M |
| Operating cash flows paid for operating lease | $2.6M | $1.3M | $1.1M |
| Cash paid for interest | $12.7M | $12.7M | $6.8M |
| Cash paid for income taxes | $2.2M | $1.0M | $125.0K |
| Accrued milestone payments classified as intangible assets, net | $35.0M | $0 | $0 |
| Right-of-use assets obtained in exchange for lease liabilities | $2.4M | $9.6M | $473.0K |
| Decrease in ROU assets and lease liabilities due to lease modification | $649.0K | $723.0K | $0 |
| Stock-based compensation capitalized to inventory | $688.0K | $1.1M | $822.0K |
| Conversion of convertible notes, net into shares of common stock | $24.0K | $0 | $0 |
| Issuance of common stock in connection with settlement of Contingent Milestone and Indemnification Holdback liabilities | $0 | $0 | $5.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Mirum Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
20202025
- Chief executive officerChristopher Peetz Jul 17, 2019 to now12
- ChairMichael G. Grey Jul 17, 2019 to Jul 24, 201913
- PresidentPeter Radovich Jan 25, 2024 to now14
- PresidentChristopher Peetz Jul 17, 2019 to Jan 9, 202412
- Chief financial officerEric Bjerkholt Sep 12, 2023 to now15
- Chief operating officerPeter Radovich Apr 30, 2020 to now16
Board members and other officers (19)
- Chief Medical OfficerRobert Paul Myers Sep 22, 2026 to now17
- CHIEF MEDICAL OFFICERJoanne Quan Jan 18, 2024 to now18
- SVP, Global ControllerJolanda Howe May 9, 2023 to now19
- Chief Development OfficerLara Longpre Jul 17, 2019 to Mar 18, 202420
- Chief Scientific OfficerPamela Vig Jul 17, 2019 to Jun 25, 202421
- Chief Medical OfficerEdwin Jonathan Tucker Oct 28, 2019 to Nov 15, 202122
- Board memberTimothy P. Walbert Apr 6, 2023 to now23
- Board memberSaira Ramasastry Jun 6, 2022 to now24
- Board memberLon Cardon Dec 19, 2022 to now25
- Board memberCarol L. Brosgart Jun 8, 2021 to Jun 6, 202226
- Board memberWilliam Fairey Aug 20, 2021 to now27
- Board memberMichael G. Grey Jan 2, 2020 to now28
- Board memberChristopher Peetz Jul 17, 2019 to now12
- Board memberEdward T. Mathers Jul 17, 2019 to Jun 6, 202229
- Board memberLaura Brege Jul 17, 2019 to now30
- Board memberLaurent Fischer Jul 17, 2019 to now31
- Board memberNiall O'Donnell Jul 17, 2019 to Nov 15, 202232
- Board memberPatrick J. Heron Jul 17, 2019 to now33
- Board memberTiba Aynechi Jul 17, 2019 to Jul 17, 201934
Timeline
Filings
471 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 246 insider forms, 50 large holders, 1 private raises, 88 other. The latest 20:
- Oct 14, 20264 EDGAR
- Oct 13, 20268-K EDGAR
- Oct 6, 20264 EDGAR
- Sep 28, 20268-K EDGAR
- Sep 22, 20263 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 20264 EDGAR
- Sep 8, 20268-K EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
- Aug 19, 20264 EDGAR
- Aug 18, 2026144 EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20264 EDGAR
- Aug 11, 2026144 EDGAR
- Aug 11, 20264 EDGAR
- Aug 10, 2026144 EDGAR
- Aug 6, 2026SCHEDULE 13G EDGAR
The 471 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 50 such filings since October 2021, the latest 10:
- Aug 13, 2026SCHEDULE 13G/A
- Aug 6, 2026SCHEDULE 13G
- Apr 27, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 13, 2026SCHEDULE 13G/A
- Jan 27, 2026SCHEDULE 13D/A
- Dec 5, 2025SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Jan 23, 2026Raised $68.5 million in a private offering of equity Form D: 2 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,679,684 | $899.1M | 19.6% | No change |
| Jupiter Topco LLC | 5,909,184 | $691.7M | 0.3% | New |
| BlackRock, Inc. | 4,390,063 | $513.9M | 0.0% | +543,533 |
| Fmr LLC | 3,670,314 | $429.7M | 0.0% | +1,704,939 |
| Vanguard Portfolio Management LLC | 2,377,019 | $278.3M | 0.0% | +944,936 |
| Vanguard Capital Management LLC | 2,254,109 | $263.9M | 0.0% | −160,667 |
| State Street Corp | 2,170,689 | $254.1M | 0.0% | +226,408 |
| William Blair Investment Management, LLC | 1,404,741 | $164.5M | 0.5% | +1,069,072 |
| Geode Capital Management, LLC | 1,393,908 | $163.2M | 0.0% | +133,905 |
| Invesco Ltd. | 1,364,084 | $159.7M | 0.0% | +1,078,848 |
| Wellington Management Group Llp | 1,309,987 | $153.4M | 0.0% | −24,822 |
| Eventide Asset Management, LLC | 1,248,389 | $146.2M | 2.0% | −160,482 |
| Tang Capital Management LLC | 1,236,027 | $144.7M | 6.6% | No change |
| Capital World Investors | 1,153,480 | $135.0M | 0.0% | +429,065 |
| Franklin Resources Inc | 1,152,770 | $135.0M | 0.0% | +437,966 |
| Novo Holdings A/s | 1,125,000 | $131.7M | 7.6% | −200,000 |
| TCG Crossover Management, LLC | 1,062,049 | $124.3M | 3.0% | No change |
| Bvf Inc/il | 1,056,027 | $123.6M | 3.2% | −528,700 |
| Polar Capital Holdings Plc | 845,524 | $99.0M | 0.3% | +562,040 |
| Rock Springs Capital Management LP | 798,145 | $93.4M | 4.6% | −13,149 |
| Nomura Asset Management International Inc. | 752,044 | $88.0M | 0.1% | +346,723 |
| Ameriprise Financial Inc | 726,694 | $85.1M | 0.0% | +507,439 |
| Two Sigma Investments, LP | 690,318 | $80.8M | 0.1% | −84,523 |
| Bank of New York Mellon Corp | 669,974 | $78.4M | 0.0% | +85,451 |
| Clearbridge Investments, LLC | 639,734 | $74.9M | 0.1% | −32,136 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitemirumpharma.com1
- WikidataQ113503532
- SEC EDGARCIK 1759425
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARMichael G. Grey, Chair
- 14SEC EDGARPeter Radovich, President
- 15
- 16
- 17
- 18SEC EDGARJoanne Quan, CHIEF MEDICAL OFFICER
- 19SEC EDGARJolanda Howe, SVP, Global Controller
- 20
- 21SEC EDGARPamela Vig, Chief Scientific Officer
- 22
- 23SEC EDGARTimothy P. Walbert, Board member
- 24SEC EDGARSaira Ramasastry, Board member
- 25SEC EDGARLon Cardon, Board member
- 26SEC EDGARCarol L. Brosgart, Board member
- 27SEC EDGARWilliam Fairey, Board member
- 28SEC EDGARMichael G. Grey, Board member
- 29SEC EDGAREdward T. Mathers, Board member
- 30SEC EDGARLaura Brege, Board member
- 31SEC EDGARLaurent Fischer, Board member
- 32SEC EDGARNiall O'Donnell, Board member
- 33SEC EDGARPatrick J. Heron, Board member
- 34SEC EDGARTiba Aynechi, Board member